OpenAlex
PricingAboutJobs
Log inGet started
Work

No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial

HTML

Year: 2017
Type: article
Source: Diabetes Care
DOI: 10.2337/dc17-1956
Authors: Laszlo Hegedüs, Steven I. Sherman, R. Michael Tuttle, Bernt J. von Scholten, Søren Rasmussen, Julie D. Karsbøl, Gilbert H. Daniels
Institutions: Odense University Hospital, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Novo Nordisk (Denmark), Harvard University, Massachusetts General Hospital
Language: English

Topic: Diabetes Treatment and Management
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: liraglutide, calcitonin, C-cell hyperplasia, medullary thyroid carcinoma, type 2 diabetes, GLP-1 receptor agonists, thyroid cancer risk, long-term safety, cardiovascular outcomes, LEADER trial
SDG: Good health and well-being

Open Access status: closed

Funder: Novo Nordisk
OpenAlex ID: W2778933123
FWCI: 3.147
Cites: 10
Cited by: 70
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security